Evidence map›Paper›PMID 42123678›Full record

ReviewInternational journal of molecular sciences2026

In Vitro Models of Sturge-Weber Syndrome: Strengths, Limitations, and Future Goals.

Ashleigh B Manney, Christina L Nemeth, Anne M Comi

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ashleigh B ManneyDepartment of Neurodevelopmental Medicine, Kennedy Krieger Institute, Baltimore, MD 21205, USA.
Christina L NemethDepartment of Neurodevelopmental Medicine, Kennedy Krieger Institute, Baltimore, MD 21205, USA.
Anne M ComiDepartment of Neurodevelopmental Medicine, Kennedy Krieger Institute, Baltimore, MD 21205, USA.

Funding

Faneca 66 Foundation NA
6 · The paper itself

Abstract

Sturge-Weber Syndrome (SWS) is a rare congenital disorder presenting with a vascular malformation in the upper face and brain, causing impaired blood-brain barrier function and perfusion, increased calcium signaling, inflammation, and seizures. All these neuropathologic processes result in injury to the brain. The somatic GNAQ R183Q variant, which accounts for the majority of SWS cases, increases signaling through MAPK, PI3K, mTOR, and inflammatory pathways, primarily in endothelial cells. The discovery of this variant enabled the creation of transgenic and genetic animal and cell culture models. Generating in vitro models has been challenging due to the mosaic nature of SWS, and attempts to separate unaffected from mutant cells in primary culture have failed, limiting the utility of in vitro work. Ongoing in vitro work seeks to overcome these limitations, shape our understanding of SWS, and lead to translational advances in treatment and prevention by studying the affected molecular pathways and identifying future targets for therapy.

Indexed as

Sturge-Weber SyndromeAnimalsGTP-Binding Protein alpha Subunits, Gq-G11HumansMutationSignal TransductionGTP-Binding Protein alpha Subunits, Gq-G11GNAQin vitro modelsmosaic expressionSturge-Weber syndrome

Identifiers

PMID42123678
PMCPMC13163291

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.